» Articles » PMID: 15983

Escherichia Coli Mutants Deficient in the Aspartate and Aromatic Amino Acid Aminotransferases

Overview
Journal J Bacteriol
Specialty Microbiology
Date 1977 Apr 1
PMID 15983
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Two new mutations are described which, together, eliminate essentially all the aminotransferase activity required for de novo biosynthesis of tyrosine, phenylalanine, and aspartic acid in a K-12 strain of Escherichia coli. One mutation, designated tyrB, lies at about 80 min on the E. coli map and inactivates the "tyrosine-repressible" tyrosine/phenylalanine aminotransferase. The second mutation, aspC, maps at about 20 min and inactivates a nonrespressible aspartate aminotransferase that also has activity on the aromatic amino acids. In ilvE- strains, which lack the branched-chain amino acid aminotransferase, the presence of either the tyrosine-repressible aminotransferase or the aspartate aminotransferase is sufficient for growth in the absence of exogenous tyrosine, phenylalanine, or aspartate; the tyrosine-repressible enzyme is also active in leucine biosynthesis. The ilvE gene product alone can reverse a phenylalanine requirement. Biochemical studies on extracts of strains carrying combinations of these aminotransferase mutations confirm the existence of two distinct enzymes with overlapping specificities for the alpha-keto acid analogues of tyrosine, phenylalanine, and aspartate. These enzymes can be distinguished by electrophoretic mobilities, by kinetic parameters using various substrates, and by a difference in tyrosine repressibility. In extracts of an ilvE- tyrB- aspC- triple mutant, no aminotransferase activity for the alpha-keto acids of tyrosine, phenylalanine, or aspartate could be detected.

Citing Articles

Metabolic capabilities are highly conserved among human nasal-associated species in pangenomic analyses.

Tran T, F Escapa I, Roberts A, Gao W, Obawemimo A, Segre J mSystems. 2024; 9(12):e0113224.

PMID: 39508593 PMC: 11651106. DOI: 10.1128/msystems.01132-24.


Sustainable production of the drug precursor tyramine by engineered Corynebacterium glutamicum.

Poethe S, Junker N, Meyer F, Wendisch V Appl Microbiol Biotechnol. 2024; 108(1):499.

PMID: 39476177 PMC: 11525245. DOI: 10.1007/s00253-024-13319-8.


Purine limitation prevents the exogenous pyridoxal 5'-phosphate accumulation of mutants.

Ezekiel K, Downs D Microbiol Spectr. 2024; :e0207524.

PMID: 39436136 PMC: 11619424. DOI: 10.1128/spectrum.02075-24.


Modulators of a robust and efficient metabolism: Perspective and insights from the Rid superfamily of proteins.

Fulton R, Downs D Adv Microb Physiol. 2023; 83:117-179.

PMID: 37507158 PMC: 10642521. DOI: 10.1016/bs.ampbs.2023.04.001.


Metabolic capabilities are highly conserved among human nasal-associated species in pangenomic analyses.

Tran T, F Escapa I, Roberts A, Gao W, Obawemimo A, Segre J bioRxiv. 2023; .

PMID: 37333201 PMC: 10274666. DOI: 10.1101/2023.06.05.543719.


References
1.
RUDMAN D, Meister A . Transamination in Escherichia coli. J Biol Chem. 1953; 200(2):591-604. View

2.
Adelberg E, Umbarger H . Isoleucine and valine metabolism in Escherichia coli. V. alpha-Ketoisovaleric acid accumulation. J Biol Chem. 1953; 205(1):475-82. View

3.
Vogel H, Bonner D . Acetylornithinase of Escherichia coli: partial purification and some properties. J Biol Chem. 1956; 218(1):97-106. View

4.
Gross J, ENGLESBERG E . Determination of the order of mutational sites governing L-arabinose utilization in Escherichia coli B/r bv transduction with phage Plbt. Virology. 1959; 9:314-31. DOI: 10.1016/0042-6822(59)90125-4. View

5.
SILBERT D, Jorgensen S, Lin E . Repression of transaminase A by tyrosine in Escherichia coli. Biochim Biophys Acta. 1963; 73:232-40. DOI: 10.1016/0006-3002(63)90307-x. View